Patents by Inventor Aung Naing Lwin

Aung Naing Lwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1 receptor agonist bioassay
    Patent number: 8603761
    Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLPI receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: December 10, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Michalis Nicolaou, Frederick Charles Bancroft, John Patrick Herich, Aung Naing Lwin, Swati Gupta
  • GLP-1 receptor agonist bioassays
    Patent number: 8329419
    Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: December 11, 2012
    Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LP
    Inventors: Michalis Nicolaou, Frederick Charles Bancroft, John Patrick Herich, Swati Gupta, Aung Naing Lwin
  • GLP-1 RECEPTOR AGONIST BIOASSAYS
    Publication number: 20110097751
    Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.
    Type: Application
    Filed: May 15, 2009
    Publication date: April 28, 2011
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: Michalis Nicolaou, Frederick Charles Bancroft, John Patrick Herich, Aung Naing Lwin, Swati Gupta